The increase in the price target from $75 to $85 suggests that JP Morgan sees potential upside in DexCom's stock, which could lead to a positive short-term impact on the stock price. However, the Neutral rating indicates that the analyst does not see a strong enough reason to recommend buying the stock at this time.